Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.
United States Timothya Yap University Of Texas Md Anderson Cancer Center Investigational Cancer Therapeutics Cancer Medicine Cancer Center
Source: onclive.com